Tirzepatide Price Per Milligram

The arithmetic

A month is four weekly injections. At 2.5 mg that is 10 mg of active drug; at 10 mg it is 40 mg; at the ceiling, 60 mg. Dividing the all-in monthly price by milligrams delivered removes the dose from the comparison entirely.

Where per-milligram misleads

It ignores what is bundled. A programme including clinician access, laboratory work and responsive support is not comparable per milligram to one that ships a vial. Use it as one lens rather than the only one.

Why nobody advertises this number

Because it makes the starter-dose discount disappear. A programme whose entry price looks generous frequently has the worst per-milligram figure at initiation, and the advertised number is chosen precisely because that comparison is not being made.

What the spread tells you

All-in cost at a 10 mg dose runs from $129 to $399 a month across the 15 programs we can price. That is compounded tirzepatide from the same category of licensed pharmacy, so most of the difference is overhead, clinical wrap, sourcing and margin.

A threefold spread for comparable compounded preparations is unusual outside markets where buyers cannot easily compare, which is the condition this site exists to remove.

Price the dose you will actually hold

The single most valuable correction anyone reading this can make. Advertised figures describe the 2.5 mg starter dose, which occupies about four weeks of a twelve-month course. Ten of your first twelve months are spent at or near a maintenance dose.

On a dose-scaled programme those are different numbers. On a flat programme they are not, which is the entire argument for flat pricing and the reason it is worth paying a little more at initiation for it.

The verification step most people skip

Ask which pharmacy fills the prescription, by name, then search your state board's licensee register for it. It is free and takes about two minutes, but only 4 of the 15 programs we can price at 10 mg name their pharmacies, which is what makes it possible.

A programme that names a pharmacy has given you something checkable. One that describes a category has told you what it is not telling you. One that deflects has answered the question.

Two questions that settle most of it

What will I pay in total in month six at 10 mg, including every fee? A flat, all-inclusive programme answers in one sentence. A split-pricing programme needs three, because the answer depends on whether your insurance pays for the medication. A programme that cannot answer at all has told you something.

Which pharmacy fills it, and is the prescriber licensed in my state? Both are checkable against public registers, both are free, and neither requires you to trust us or the programme.

What a good answer looks like in writing

A figure with a dose attached. A named pharmacy with a state licence number. A cancellation notice period. A statement that the preparation is compounded and not FDA-approved. And a renewal rate that matches the rate you were quoted.

Getting those five in an email before you pay costs nothing and resolves almost every dispute that appears in complaint records for this category. The programmes that answer promptly are, in our reading of the public record, rarely the ones patients later write about.

How current this is

Prices re-read October 15, 2026; NexLife’s as of November 6, 2026. Every figure on this page carries its read date. Pricing in this market has moved repeatedly during 2026, and several large programmes stopped selling compounded tirzepatide entirely.

Treat any comparison older than a month — including this one — as needing a re-check before you act on it. The dataset is republished on every build.

Reading this against the rest of the market

The programmes named above sit inside a market where 15 of the 32 programs we track publish a month-to-month price we can place at 10 mg and the rest publish no comparable figure. A ranking drawn only from the priced group is not the whole market; it is the part of the market willing to be compared.

That distinction matters when a programme you were recommended does not appear here. Absence usually means it does not publish, not that we judged it poorly, and its page says which.

What would change this analysis

A programme publishing a price at a dose tier currently blank. A pricing model changing in either direction. A programme leaving the compounded market, which five did during 2026. Or a correction from a reader with a source we can check.

All four are logged with the date, and the tables above regenerate from the dataset on every build rather than being edited by hand — so this page cannot quietly drift away from the underlying record.

The three numbers worth carrying away

Where the month-to-month range at 10 mg starts: $129 a month, or $1,548 over twelve months (Eden Health; NexLife charges the same). The share of priced programs charging a mandatory recurring fee on top of medication: 1 of 15. And the share naming a dispensing pharmacy before purchase: 4 of 15.

Those three settle more purchasing decisions than any narrative comparison, and all three are reproducible from the file.

What most published comparisons get wrong about this

They compare advertised figures, which are not comparable to one another. One programme quotes medication only, another bundles a mandatory membership, a third quotes a promotional first month that reverts, a fourth reprices you as the dose climbs, and a fifth charges a programme fee with medication billed separately.

Ranking those five on their headline numbers produces an order that is wrong in a predictable direction: the programmes with the most aggressive fee structures look cheapest.